When the 70th World Health Assembly (WHA) begins today in Geneva, Switzerland, it will be one of historic measure. Not only because the WHA be electing a new Director-General of the World Health Organization (WHO), but also because of its sheer scope.

For years, little was known of the typhoid burden in Africa, even though outbreaks of multi-drug resistant typhoid is becoming increasingly common. This lack of information spurred the Bill and Melinda Gates Foundation to fund the Typhoid Fever Surveillance in Africa Program (TSAP) through the International Vaccine Institute, a first-of-its-kind study established to shed light on true extent of the typhoid burden and multi-drug resistance distribution on the continent. The results from the TSAP, recently published in the Lancet Global Health, represent the most comprehensive and rigorous analysis of typhoid in Africa and could change our understanding of the disease burden across the continent.

Vaccines are healthcare’s first line of defense. From polio to pertussis, rubella to rotavirus, vaccination has saved more lives than any other medical advance in recent history.

Diseases

The Sabin Vaccine Institute works to extend the benefits of immunization to all people by enabling vaccine access and uptake. Sabin brings together national government officials, policy makers, immunization specialists, researchers and advocates to supply decision makers with the data and expertise they need to make evidence-based decisions on vaccines. Our work includes a number of diseases, including:

Typhoid Research & Advocacy

One-third of the world’s population is at risk of contracting typhoid, a systemic bacterial infection spread through contaminated food and water that kills more than 128,000 people each year, primarily children in low-income countries. Caused by Salmonella enterica serotype Typhi (S. Typhi), typhoid is an acute illness that is often misdiagnosed because its symptoms – prolonged fever, headache, nausea, constipation, loss of appetite and diarrhea – are so common.

Global Consensus

Working together to shape global health solutions is more important than ever. Sabin seeks to extend the benefits of immunization to everyone by bringing together representatives from across the private and public sectors to identify key challenges facing global immunization and help establish best practices and recommendations to overcome them.

Supporting Evidence-Based Decisions

Vaccine introduction, policy and financing are complex issues, and countries must achieve ambitious immunization targets with limited available resources. To make informed decisions for the health of their people, decision makers need accurate, up-to-date information to identify vulnerable populations, assess burden of disease, evaluate vaccine efficacy and cost-effectiveness, and measure the efficiency of immunization programs.

Introduction & Expansion

Over the last decade, many new vaccines have been developed, but the promise of these vaccines is only fulfilled when they are administered around the world. To deliver health to as many people as possible, countries need accurate, high-quality data to ensure their resources are used effectively.

Sabin brings together national government officials, policy makers, immunization specialists, researchers and advocates to supply decision makers with the data and expertise they need to make evidence-based decisions on vaccines.

Immunization Policy & Financing

Vaccines are an essential public good that governments provide to their citizens. Vaccine costs are rising, often faster than public immunization budgets are expanding. Many countries currently eligible for financial support from Gavi, the Vaccine Alliance, are graduating or will soon graduate from this support. These countries must therefore depend on domestic sources to maintain or improve their immunization programs.

Pages

Subscribe to RSS - Access & Uptake